Overview of the treatment of heart failure

American Journal of Cardiology

Volumn 80, Issue 11 A, 1997, Pages

  Cohn, Jay N ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; ISOSORBIDE DINITRATE; THIAZIDE DIURETIC AGENT;

CLINICAL FEATURE; CONFERENCE PAPER; DRUG EFFECT; DYSPNEA; EXERCISE TOLERANCE; FUNCTIONAL ASSESSMENT; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOTENSION; LEG EDEMA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT PLANNING; UREMIA;

EID: 0030660244     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00843-6     Document Type: Conference Paper

References (43)

1. Cohn JN. The management of chronic heart failure. N Engl J Med. 335:1996;490-498.
2. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 325:1991;303-310.
3. Cohn JN, Johnson GR, Shabetai R, Loeb H, Tristani F, Rector T, Smith R, Fletcher R. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation. 87:(suppl VI):1993;VI-5-VI-16.
4. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B. Effect of vasodilator therapy on mortality in chronic congestive heart failure results of a Veterans Administration Cooperative Study . N Engl J Med. 314:1986;1547-1552.
5. A randomized trial of β-blockade in heart failure the Cardiac Insufficiency Bisoprolol Study (CIBIS) . Circulation. 90:1994;1765-1773.
6. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
7. Konstam MA, Dracup K, Baker DW, Bottorff MB, Brooks NH, Dacey RA, Dunbar SB, Jackson AB, Jessup M, Johnson JC, Jones RH, Luchi RJ, Massie BM, Pitt B, Rose EA, Rubin LJ, Wright RF, Hadorn DC. Heart Failure: Evaluation and Care of Patients With Left-Ventricular Systolic Dysfunction. Clinical Practice Guideline No. 11. Rockville, MD: Agency for Health Care Policy and Research; 1994. Public Health Service, US Dept of Health and Human Services. ACHPR Publication No. 94-0612.
8. Passamani E, Davis KB, Gillespie MJ, Killip T. A randomized trial of coronary artery bypass surgery survival of patients with a low ejection fraction . N Engl J Med. 312:1985;1665-1671.
9. O'Connell JB, Bourge RC, Costanzo-Nordin MR, Driscoll DJ, Morgan JP, Rose EA, Uretsky BF. Cardiac transplantation recipient selection, donor procurement, and medical follow-up. A statement for health professionals from the Committee on Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association . Circulation. 86:1992;1061-1079.
10. Taylor SH. Refocus on diuretics in the treatment of heart failure. Eur Heart J. 16:(suppl F):1995;7-15.
11. Smith TW, Kelly RA, Warner Stevenson L, Braunwald E. Management of heart failure. In: Braunwald E, ed. Heart Disease. A Textbook of Cardiovascular Medicine. Philadelphia: WB Saunders, 1996:492-514.
12. Weiner IM. Drugs affecting renal function and electrolyte metabolism. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York: Pergamon Press, 1990:713-731.
13. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure clinical and neuroendocrine effects of introducing diuretics . Br Heart J. 57:1987;17-22.
14. Cody RJ, Covit AB, Schaer GL, Laragh JH, Sealey JE, Feldschuh J. Sodium and water balance in chronic congestive heart failure. J Clin Invest. 77:1986;1441-1452.
15. Kelly RA, Smith TW. Nitric oxide and nitrovasodilators similarities, differences, and interactions . Am J Cardiol. 77:1996;2C-7C.
16. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol. 2:1983;755-763.
17. Effects of enalapril on mortality in severe congestive heart failure results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) . N Engl J Med. 316:1987;1429-1435.
18. Garrison JC, Peach MJ. Renin and angiotensin. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York: Pergamon Press, 1990:749-763.
19. Levine TB, Franciosa JA, Vrobel T, Cohn JN. Hyponatraemia as a marker for high renin heart failure. Br Heart J. 47:1982;161-166.
20. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 327:1992;685-691.
21. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:1991;293-302.
22. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA. 259:1988;539-544.
23. Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ, Smith CK, Van Voorhees L, Gourley LA, Jolly MK. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med. 329:1993;1-7.
24. Abernathy GT, Abrams J, Akhtar S, et al. Rationale, design, implementation, and baseline characteristics of patients in the DIG trial a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure . Control Clin Trials. 17:1996;77-97.
25. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 336:1997;525-533.
26. Packer M. End of the oldest controversy in medicine Are we ready to conclude the debate on digitalis? N Engl J Med. 336:1997;575-576.
27. Francis GS, McDonald KM, Cohn JN. Neurohumoral activation in preclinical heart failure remodeling and the potential for intervention . Circulation. 87:(suppl IV):1993;IV-90-IV-96.
28. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephrine, plasma renin activity, and congestive heart failure relations to survival and the effects of therapy in V-HeFT II . Circulation. 87:(suppl VI):1993;VI-40-VI-48.
29. Reiter MJ. Effects of mechano-electrical feedback potential arrhythmogenic influence in patients with congestive heart failure . Cardiovasc Res. 32:1996;44-51.
30. Cohn JN. Critical review of heart failure the role of left ventricular remodeling in the therapeutic response . Clin Cardiol. 18:(9 suppl 4):1995;IV4-IV12.
31. Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, Shelton B. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction Results of the SOLVD echocardiography substudy . Circulation. 91:1995;2573-2581.
32. McDonald KM, Rector T, Carlyle PF, Francis GS, Cohn JN. Angiotensin-converting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage. J Am Coll Cardiol. 24:1994;1762-1768.
33. Pouleur H, van Eyll C, Hanet C, Cheron P, Charlier AA, Rousseau MF. Long-term effects of xamoterol on left ventricular diastolic function and late remodeling a study in patients with anterior myocardial infarction and single-vessel disease . Circulation. 77:1988;1081-1089.
34. Bashir Y, Sneddon JF, O'Nunain S, Paul VE, Gibson S, Ward DE, Camm AJ. Comparative electrophysiological effects of captopril or hydralazine combined with nitrate in patients with left ventricular dysfunction and inducible ventricular tachycardia. Br Heart J. 67:1992;355-360.
35. Dietz R, Waas W, Susselbeck T, Willenbrock R, Osterziel KJ. Improvement of cardiac function by angiotensin converting enzyme inhibition sites of action . Circulation. 87:(suppl 5):1993;IV108-IV116.
36. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 342:1993;821-828.
37. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med. 332:1995;80-85.
38. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JC, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction Results of the Survival and Ventricular Enlargement Trial . N Engl J Med. 327:1992;669-677.
39. Bourassa MG, Gurne O, Bangdiwala SI, Ghali JK, Young JB, Rousseau M, Johnstone DE, Yusuf S. Natural history and patterns of current practice in heart failure The Studies of Left Ventricular Dysfunction (SOLVD) Investigators . J Am Coll Cardiol. 22:(4 suppl A):1993;14A-19A.
40. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker ML, Marshall G, Kelly P, Deitchman D, Anderson JL. Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation. 89:1994;1632-1642.
41. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy a double-blind, randomized, placebo-controlled trial . Circulation. 72:1985;536-546.
42. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 342:1993;1441-1446.
43. Design of the Beta-Blocker Evaluation Survival Trial (BEST). Am J Cardiol. 75:1995;1220-1223.